What's Going On With Eli Lilly And Company Shares Thursday?
Portfolio Pulse from Dylan Berman
Eli Lilly and Company (NYSE:LLY) shares are down 6.39% on Thursday, likely due to competition concerns following positive weight loss data from Roche's Phase I clinical trial for CT-996, a treatment for type 2 diabetes and obesity.
July 18, 2024 | 4:32 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Eli Lilly shares are experiencing a decline, likely due to competition concerns after Roche announced positive Phase I data for its weight loss and diabetes treatment, CT-996.
The decline in Eli Lilly's stock price is likely due to investor concerns about increased competition in the weight loss and diabetes treatment market following Roche's positive clinical trial results for CT-996.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100